Amoeba SA (FR:ALMIB)
:ALMIB
Want to see FR:ALMIB full AI Analyst Report?
Top Page
Amoeba SA
(ALMIB)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.86
▼(-20.09% Downside)
Action:Upgraded
Date:03/27/26
The score is driven primarily by very weak financial performance (revenue collapse, persistent losses and cash burn, and negative equity with rising debt). Technical indicators add additional downside bias as the stock trades below key moving averages with negative momentum, while valuation provides limited support due to loss-making results and no dividend yield.
Positive Factors
Proprietary IP
Owning a unique microorganism provides a durable product differentiation and potential regulatory/market exclusivity across applications. This IP can support long-term licensing, defendable product positioning and higher barriers to entry if commercialized and registered in target markets.
Negative Factors
Revenue Collapse
A complete collapse of revenue is a structural red flag: it prevents leveraging fixed costs, halts organic reinvestment, and undermines credibility with distributors and regulators. Absent sustained sales, product validation and long-term commercial viability are highly uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary IP
Owning a unique microorganism provides a durable product differentiation and potential regulatory/market exclusivity across applications. This IP can support long-term licensing, defendable product positioning and higher barriers to entry if commercialized and registered in target markets.
Read all positive factors
Amoeba SA (ALMIB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€69.93M
Dividend YieldN/A
Average Volume (3M)268.33K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth-2.77%
CountryFR
Employees20
SectorServices
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.13
Shares Outstanding77,817,220
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio1.14
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Amoeba SA Business Overview & Revenue Model
Company Description
Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protect...
How the Company Makes Money
Amoéba SA’s business model is to generate revenue from the development, manufacturing, and sale (or licensed distribution) of products formulated from its proprietary amoeba strain for biocontrol and water/industrial uses. Key revenue streams incl...
Amoeba SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 601.60K | 664.31K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -805.57K | -1.71M | -1.01M | -858.95K |
| EBITDA | -7.47M | -5.38M | -13.74M | -5.35M | -5.01M |
| Net Income | -8.30M | -6.59M | -14.30M | -8.02M | -7.82M |
Balance Sheet | |||||
| Total Assets | 10.13M | 5.65M | 6.29M | 12.39M | 14.50M |
| Cash, Cash Equivalents and Short-Term Investments | 4.72M | 458.94K | 519.33K | 5.53M | 7.28M |
| Total Debt | 12.24M | 12.07M | 4.92M | 2.36M | 12.50M |
| Total Liabilities | 15.49M | 16.06M | 10.23M | 4.23M | 14.30M |
| Stockholders Equity | -5.36M | -10.41M | -3.94M | 8.16M | 213.68K |
Cash Flow | |||||
| Free Cash Flow | -7.42M | -4.78M | -12.59M | -5.71M | -6.05M |
| Operating Cash Flow | -6.13M | -4.22M | -6.50M | -5.40M | -5.90M |
| Investing Cash Flow | -1.30M | -2.01M | -2.81M | -212.13K | -140.65K |
| Financing Cash Flow | 11.69M | 6.16M | 4.30M | 3.87M | 4.98M |
Amoeba SA Technical Analysis
Negative
1.08
Price Trends
0.90
Negative
0.93
Negative
0.95
Negative
Market Momentum
<0.01
Negative
50.04
Neutral
44.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMIB, the sentiment is Negative. The current price of 1.08 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.90, and above the 200-day MA of 0.95, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.04 is Neutral, neither overbought nor oversold. The STOCH value of 44.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMIB.
Amoeba SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €69.93M | 26.32 | 18.06% | 0.55% | 9.12% | -10.02% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
47 Neutral | €7.15M | 4.91 | 0.11% | ― | -4.08% | -112.93% | |
42 Neutral | €69.93M | -5.89 | ― | ― | ― | -2.77% | |
41 Neutral | €50.13M | 6.33 | ― | ― | ― | ― | |
38 Underperform | €61.20M | -2.54 | -514.29% | ― | 39.07% | 41.33% |
* Services Sector Average
FR:ALMIB
Amoeba SA
0.90
-0.39
-30.31%
FR:ALJXR
Archos
0.18
-0.05
-21.40%
FR:ALATA
Atari SA
21.93
-7.97
-26.66%
FR:ALCLA
Claranova SA
0.88
-1.95
-68.85%
FR:BIG
Bigben Interactive
0.39
-0.51
-56.56%
FR:COH
Coheris
12.10
4.18
52.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.